Product Name: IL-31 Antibody
Species Reactivity: Mouse
Tested Applications: ELISA, IHC-P, WB
Applications: IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 – 10 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: IL-31 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of mouse IL-31.The immunogen is located within amino acids 30 – 80 of IL-31.
Host Species: Rabbit
Purification: IL-31 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 41060-15-5
Product: Nifursol
Buffer: IL-31 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: IL-31 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: IL-31 Antibody: 1700013B14Rik, Interleukin-31, IL-31
Accession NO.: AAS82846
Protein Ino: 46241139
Official Symbol: Il31
Geneid: 76399
Background: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
PubMed ID:http://aac.asm.org/content/26/3/419.abstract
